Table 2.
Composite SARS-CoV-2 IgG levels compared between time points for subgroups of study participants divided by gender, age, race, occupation role, and presence of co-morbidities.
| Variable | Category | N | Composite SARS-CoV-2 IgG MFI, mean (95% CI) a | p-value b | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre-vaccine | 2mo | 4mo | 6mo | Pre vs. 2mo | 2mo vs. 4mo | 4mo vs. 6mo | ||||
| Overall | 240 | 175 (0, 408) | 3829 (3665, 3993) | 4471 (4263, 4679) | 4396 (4166, 4625) | <0.001* | <0.001* | 0.959 | ||
| Sex c | Female | 176 | 146 (0, 424) | 3856 (3669, 4043) | 4450 (4217, 4682) | 4506 (4243, 4770) | <0.001* | 0.001* | 0.999 | |
| Male | 63 | 250 (0, 688) | 3744 (3418, 4071) | 4541 (4087, 4995) | 3878 (3407, 4348) | <0.001* | 0.077 | 0.430 | ||
| Female vs. male | 0.999 | 0.999 | 0.999 | 0.301 | ||||||
| Age | <55 years | 196 | 187 (0, 453) | 3814 (3635, 3992) | 4515 (4282, 4748) | 4524 (4265, 4784) | <0.001* | <0.001* | 0.999 | |
| ≥55 years | 44 | 122 (0, 631) | 3908 (3499, 4316) | 4305 (3852, 4759) | 3939 (3448, 4429) | <0.001* | 0.877 | 0.949 | ||
| <55 years vs. ≥55 years | 0.999 | 0.999 | 0.993 | 0.434 | ||||||
| Race | Asian | 92 | 112 (0, 505) | 3654 (3395, 3912) | 4463 (4133, 4793) | 4250 (3906, 4595) | <0.001* | 0.009* | 0.999 | |
| White | 76 | 141 (0, 518) | 3846 (3544, 4149) | 4136 (3768, 4503) | 4365 (3969, 4762) | <0.001* | 0.997 | 0.999 | ||
| Latino | 39 | 369 (0, 990) | 4223 (3817, 4629) | 4978 (4499, 5458) | 4834 (4275, 5392) | <0.001* | 0.501 | 0.999 | ||
| Other | 33 | 167 (0, 869) | 3824 (3406, 4242) | 4650 (4004, 5295) | 4327 (3379, 5274) | <0.001* | 0.709 | 0.999 | ||
| By race | 0.999 | 0.999 | <0.001* | <0.001* | ||||||
| NP reactivity | Non-reactive | 199 | 26 (0, 191) | 3712 (3595, 3828) | 4413 (4196, 4630) | 4362 (4118, 4606) | <0.001* | <0.001* | 0.999 | |
| Reactive | 41 | 1093 (671, 1514) | 4211 (3958, 4464) | 4972 (4352, 5592) | 4610 (4012, 5208) | <0.001* | 0.388 | 0.991 | ||
| Non-reactive vs. reactive | 0.084 | 0.435 | 0.703 | 0.995 | ||||||
| Patient care | Patient care role | 179 | 122 (-162, 407) | 3755 (3573, 3938) | 4436 (4186, 4685) | 4320 (4041, 4599) | <0.001* | <0.001* | 0.998 | |
| Non-patient care role | 61 | 285 (-134, 705) | 4115 (3747, 4484) | 4563 (4189, 4937) | 4560 (4157, 4964) | <0.001* | 0.658 | 0.999 | ||
| By patient care role | 0.998 | 0.674 | 0.999 | 0.979 | ||||||
| Hypertension | No hypertension | 210 | 184 (-75, 444) | 3839 (3666, 4012) | 4543 (4315, 4771) | 4415 (4161, 4669) | <0.001* | <0.001* | 0.995 | |
| Hypertension | 30 | 102 (-465, 669) | 3747 (3233, 4261) | 4117 (3610, 4623) | 4293 (3749, 4838) | <0.001* | 0.964 | 0.999 | ||
| No hypertension vs. hypertension | 0.999 | 0.999 | 0.804 | 0.999 | ||||||
| Obesity/diabetes | No obesity and diabetes | 193 | 127 (-140, 394) | 3791 (3613, 3968) | 4419 (4189, 4649) | 4329 (4070, 4588) | <0.001* | <0.001* | 0.999 | |
| Obesity or diabetes | 47 | 335 (-163, 833) | 4029 (3603, 4455) | 4710 (4227, 5194) | 4646 (4148, 5145) | <0.001* | 0.378 | 0.999 | ||
| Any vs. none | 0.996 | 0.972 | 0.962 | 0.954 | ||||||
a
Composite SARS-CoV-2 IgG MFI mean and 95% confidence interval bounds are post-estimated values calculated based on the fitted regression model.
b
p-values indicate strength of evidence for change in Composite SARS-CoV-2 IgG MFI between timepoints at 2 months intervals, against a null hypothesis of no change, as estimated from Wald test on model post-estimated marginal means within each group and timepoint. Asterisks denote significant differences at p<0.05.
c
One participant self-reported as non-binary sex and was excluded for the sex-specific analysis.